2MD: Phase IIb data

A double-blind, U.S. Phase IIb trial in 62 CKD patients receiving hemodialysis showed that thrice-weekly 220-770 ng oral DP001 for 12 weeks led to a 46% reduction in PTH levels vs. a 31% increase for ...